CYTK vs. TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, SRPT, and QGEN
Should you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Cytokinetics vs.
Cytokinetics (NASDAQ:CYTK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.
In the previous week, Teva Pharmaceutical Industries had 3 more articles in the media than Cytokinetics. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 18 mentions for Cytokinetics. Teva Pharmaceutical Industries' average media sentiment score of 0.88 beat Cytokinetics' score of 0.38 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.
54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 3.4% of Cytokinetics shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Cytokinetics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.
Teva Pharmaceutical Industries has a net margin of -9.91% compared to Cytokinetics' net margin of -17,906.25%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Cytokinetics' return on equity.
Teva Pharmaceutical Industries received 515 more outperform votes than Cytokinetics when rated by MarketBeat users. However, 79.92% of users gave Cytokinetics an outperform vote while only 67.87% of users gave Teva Pharmaceutical Industries an outperform vote.
Cytokinetics currently has a consensus target price of $82.00, indicating a potential upside of 63.67%. Teva Pharmaceutical Industries has a consensus target price of $23.57, indicating a potential upside of 41.36%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cytokinetics is more favorable than Teva Pharmaceutical Industries.
Cytokinetics has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
Summary
Cytokinetics beats Teva Pharmaceutical Industries on 10 of the 19 factors compared between the two stocks.
Get Cytokinetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytokinetics Competitors List
Related Companies and Tools
This page (NASDAQ:CYTK) was last updated on 2/21/2025 by MarketBeat.com Staff
